RELATED CONTENT
NEWS
- Mid-term concerns weigh on SymBio after Japanese IPO
- Takeda claims Aurora A kinase inhibitor lead as it takes alisertib into Phase III
- Chroma/CTI plan tosedostat PhIII to avoid AML trap that caught Vion, J&J and Genzyme
- SymBio's bendamustine moves forward in first-line setting in Japan
ANALYSIS
Other Informa Analysis
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK

Section Head (m/f)
DRA International/CIS Section

Section Head (m/f)
DRA International/CIS Section

